Logo image of TNDM

TANDEM DIABETES CARE INC (TNDM) Stock Fundamental Analysis

NASDAQ:TNDM - Nasdaq - US8753722037 - Common Stock - Currency: USD

31  -1.12 (-3.49%)

After market: 31.04 +0.04 (+0.13%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to TNDM. TNDM was compared to 189 industry peers in the Health Care Equipment & Supplies industry. TNDM may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, TNDM is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

TNDM had negative earnings in the past year.
In the past year TNDM had a positive cash flow from operations.
TNDM had negative earnings in 4 of the past 5 years.
TNDM had a positive operating cash flow in 4 of the past 5 years.
TNDM Yearly Net Income VS EBIT VS OCF VS FCFTNDM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M -200M

1.2 Ratios

TNDM has a Return On Assets (-13.24%) which is comparable to the rest of the industry.
The Return On Equity of TNDM (-53.33%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -13.24%
ROE -53.33%
ROIC N/A
ROA(3y)-10.21%
ROA(5y)-8.61%
ROE(3y)-29.63%
ROE(5y)-22.2%
ROIC(3y)N/A
ROIC(5y)N/A
TNDM Yearly ROA, ROE, ROICTNDM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 1K

1.3 Margins

With a Gross Margin value of 49.79%, TNDM perfoms like the industry average, outperforming 42.78% of the companies in the same industry.
In the last couple of years the Gross Margin of TNDM has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for TNDM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 49.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.99%
GM growth 5Y0.14%
TNDM Yearly Profit, Operating, Gross MarginsTNDM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50

More info and screens

3

2. Health

2.1 Basic Checks

TNDM does not have a ROIC to compare to the WACC, probably because it is not profitable.
TNDM has more shares outstanding than it did 1 year ago.
TNDM has more shares outstanding than it did 5 years ago.
TNDM has a worse debt/assets ratio than last year.
TNDM Yearly Shares OutstandingTNDM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
TNDM Yearly Total Debt VS Total AssetsTNDM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of 1.21, we must say that TNDM is in the distress zone and has some risk of bankruptcy.
TNDM has a Altman-Z score (1.21) which is comparable to the rest of the industry.
TNDM has a Debt/Equity ratio of 1.29. This is a high value indicating a heavy dependency on external financing.
TNDM has a Debt to Equity ratio of 1.29. This is amonst the worse of the industry: TNDM underperforms 80.75% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.29
Debt/FCF N/A
Altman-Z 1.21
ROIC/WACCN/A
WACC8.56%
TNDM Yearly LT Debt VS Equity VS FCFTNDM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 2.90 indicates that TNDM has no problem at all paying its short term obligations.
TNDM's Current ratio of 2.90 is in line compared to the rest of the industry. TNDM outperforms 53.48% of its industry peers.
TNDM has a Quick Ratio of 2.32. This indicates that TNDM is financially healthy and has no problem in meeting its short term obligations.
TNDM has a Quick ratio (2.32) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.9
Quick Ratio 2.32
TNDM Yearly Current Assets VS Current LiabilitesTNDM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 44.19% over the past year.
Looking at the last year, TNDM shows a quite strong growth in Revenue. The Revenue has grown by 10.75% in the last year.
TNDM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 32.38% yearly.
EPS 1Y (TTM)44.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.89%
Revenue 1Y (TTM)10.75%
Revenue growth 3Y14.45%
Revenue growth 5Y32.38%
Sales Q2Q%31.43%

3.2 Future

The Earnings Per Share is expected to grow by 14.64% on average over the next years. This is quite good.
The Revenue is expected to grow by 11.86% on average over the next years. This is quite good.
EPS Next Y44.15%
EPS Next 2Y26.5%
EPS Next 3Y20.66%
EPS Next 5Y14.64%
Revenue Next Year19.15%
Revenue Next 2Y14.93%
Revenue Next 3Y13.84%
Revenue Next 5Y11.86%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
TNDM Yearly Revenue VS EstimatesTNDM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
TNDM Yearly EPS VS EstimatesTNDM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TNDM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TNDM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNDM Price Earnings VS Forward Price EarningsTNDM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNDM Per share dataTNDM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A more expensive valuation may be justified as TNDM's earnings are expected to grow with 20.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.5%
EPS Next 3Y20.66%

More info and screens

0

5. Dividend

5.1 Amount

TNDM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TANDEM DIABETES CARE INC

NASDAQ:TNDM (2/21/2025, 8:00:01 PM)

After market: 31.04 +0.04 (+0.13%)

31

-1.12 (-3.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)02-26 2025-02-26/amc
Inst Owners112.82%
Inst Owner Change-87.1%
Ins Owners0.47%
Ins Owner Change0.87%
Market Cap2.04B
Analysts79.31
Price Target54.21 (74.87%)
Short Float %10.64%
Short Ratio6.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.5%
Min EPS beat(2)13.62%
Max EPS beat(2)15.37%
EPS beat(4)3
Avg EPS beat(4)10.89%
Min EPS beat(4)-3.93%
Max EPS beat(4)18.48%
EPS beat(8)3
Avg EPS beat(8)-70.45%
EPS beat(12)3
Avg EPS beat(12)-179.87%
EPS beat(16)7
Avg EPS beat(16)-112.76%
Revenue beat(2)2
Avg Revenue beat(2)6.56%
Min Revenue beat(2)6.17%
Max Revenue beat(2)6.94%
Revenue beat(4)3
Avg Revenue beat(4)4.28%
Min Revenue beat(4)-4.84%
Max Revenue beat(4)8.87%
Revenue beat(8)3
Avg Revenue beat(8)0.63%
Revenue beat(12)5
Avg Revenue beat(12)0.28%
Revenue beat(16)9
Avg Revenue beat(16)3.35%
PT rev (1m)0.19%
PT rev (3m)-2.15%
EPS NQ rev (1m)-0.92%
EPS NQ rev (3m)-0.23%
EPS NY rev (1m)-0.15%
EPS NY rev (3m)-0.58%
Revenue NQ rev (1m)0.27%
Revenue NQ rev (3m)0.23%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)0.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.38
P/FCF N/A
P/OCF 323.29
P/B 8.57
P/tB 8.57
EV/EBITDA N/A
EPS(TTM)-1.73
EYN/A
EPS(NY)-1.25
Fwd EYN/A
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)0.1
OCFY0.31%
SpS13.01
BVpS3.62
TBVpS3.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.24%
ROE -53.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 49.79%
FCFM N/A
ROA(3y)-10.21%
ROA(5y)-8.61%
ROE(3y)-29.63%
ROE(5y)-22.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.99%
GM growth 5Y0.14%
F-Score5
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 1.29
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 266.62%
Cap/Sales 5.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.9
Quick Ratio 2.32
Altman-Z 1.21
F-Score5
WACC8.56%
ROIC/WACCN/A
Cap/Depr(3y)266.45%
Cap/Depr(5y)285.33%
Cap/Sales(3y)5.2%
Cap/Sales(5y)5.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.89%
EPS Next Y44.15%
EPS Next 2Y26.5%
EPS Next 3Y20.66%
EPS Next 5Y14.64%
Revenue 1Y (TTM)10.75%
Revenue growth 3Y14.45%
Revenue growth 5Y32.38%
Sales Q2Q%31.43%
Revenue Next Year19.15%
Revenue Next 2Y14.93%
Revenue Next 3Y13.84%
Revenue Next 5Y11.86%
EBIT growth 1Y38.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year101.27%
EBIT Next 3Y38.09%
EBIT Next 5Y28.08%
FCF growth 1Y-275.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-90.21%
OCF growth 3YN/A
OCF growth 5YN/A